Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in two upcoming investor conferences in March 2026. The company's participation in these events provides investors and industry stakeholders with opportunities to learn about Tonix's current commercial products and development pipeline.
Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's participation in these conferences comes at a significant time as it seeks to build investor awareness around its commercial and development-stage products.
TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the company's recently approved flagship medicine, represents the first new treatment for fibromyalgia in more than 15 years. This approval marks a significant milestone for patients suffering from this chronic pain condition and positions Tonix as a commercial-stage company with a differentiated product in a substantial market.
The company's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. These additional indications could significantly expand the drug's market potential if clinical trials prove successful.
In addition to TONMYA, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The investor conferences provide platforms for Tonix to communicate its strategy and progress to the investment community. For investors, these presentations offer insights into the company's commercial execution with TONMYA and the potential value of its development pipeline. The company's news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
For the biotechnology industry, Tonix's participation in these conferences highlights the ongoing importance of investor engagement for companies transitioning from development-stage to commercial-stage operations. The company's focus on CNS and immunology treatments addresses significant unmet medical needs in areas where new therapeutic options are needed.
The broader implications of Tonix's conference participation extend to patients who may benefit from the company's pipeline products. Successful development and commercialization of treatments for conditions like fibromyalgia, major depressive disorder, acute stress disorder, Prader-Willi syndrome, Lyme disease, and transplant rejection could improve quality of life for millions of patients worldwide.
As Tonix prepares for these investor conferences, the company's management will likely emphasize its commercial progress with TONMYA while highlighting the potential of its development pipeline. The conferences represent opportunities for the company to demonstrate its value proposition to current and potential investors while contributing to the broader dialogue about innovation in biotechnology and healthcare.
